[1] TORRE L A, SIEGEL R L, JEMAL A. Lung cancer statistics[J]. Adv Exp Med Biol, 2016, 893:1-19. [2] 眭玉霞, 邓晓宇, 伍铮, 等. 非小细胞肺癌驱动基因突变与临床病理特征的关系[J]. 临床与实验病理学杂志, 2020, 36(9):1023-1028. [3] UEDA K, KANEDA Y, HAYASHI M, et al. Relationship among genetic alterations, DNA content, and clinicopathological features in primary lung adenocarcinomas[J]. Cancer Genomics Proteomics, 2006, 3(3/4):265-270. [4] LUKOW D A, SHELTZER J M. Chromosomal instability and aneuploidy as causes of cancer drug resistance[J]. Trends Cancer, 2022, 8(1):43-53. [5] 纪晓坤, 杜芸, 王蕊, 等. HE染色细胞学涂片和FFPE标本用于EGFR突变检测的对比分析[J]. 临床与实验病理学杂志, 2020, 36(11):1344-1347. [6] 汪少华, 李丹, 黄丛改, 等. 薄层液基细胞学联合细胞DNA定量分析技术在恶性胸腔积液诊断中的应用价值[J]. 重庆医学, 2019, 48(14):2402-2406. [7] MA Z H, LI P, GAI X D, et al. DNA image cytometry ploidy analysis technique improves the detection rate of pleural effusion cytology[J]. Diagn Cytopathol, 2023, 51(3):159-165. [8] GUO C Y, HU Y, YU Q, et al. DNA aneuploidy combined with radial EBUS in the diagnosis of peripheral lung lesions[J]. Diagn Cytopathol, 2022, 50(12):565-571. [9] COSTA A F, POGERE A, PASINATO A P B F, et al. DNA image cytometry parameters to identify high-grade cervical lesions[J]. Cytopathology, 2022, 33(5):563-571. [10] TANG Y Y, LIU L J, LI C X, et al. Relationship of DNA aneuploidy with distinctive features of oral potentially malignant disorders:a cytological analysis of 748 cases[J]. J Dent Sci, 2022, 17(2):1035-1038. [11] 颜锐, 梁智勇, 李锦涛, 等. 基于深度学习和H&E染色病理图像的肿瘤相关指标预测研究综述[J]. 计算机科学, 2022, 49(2):69-82. [12] 涂超, 宁振源, 张煜. 基于多字典学习框架的肾透明细胞癌预后分析模型[J]. 中国生物医学工程学报, 2021, 40(4):385-393. [13] 阎婷, 国世星, 刘亦倩, 等. 食管鳞状细胞癌病理图像特征预后价值分析[J]. 中华肿瘤防治杂志, 2021, 28(7):513-519. [14] 王荃, 沈勤, 张泽林, 等. 基于深度学习和组织形态分析的肺癌基因突变预测[J]. 生物医学工程学杂志, 2020, 37(1):10-18. [15] DU Y, GUO X, WANG R, et al. The correlation between EGFR mutation status and DNA content of lung adenocarcinoma cells in pleural effusion[J]. J Cancer, 2020, 11(8):2265-2272. [16] MAOUNIS N F, CHORTI M, APOSTOLAKIS E, et al. Prognostic impact of Deoxyribonucleic acid (DNA) image analysis cytometry and immunohistochemical expression of Ki67 in surgically resected non-small cell lung cancers[J]. Cancer Detect Prev, 2006, 30(6):507-514. [17] 李武德, 胡思琪, 贺胜焜, 等. EGFR突变与肺癌手术患者预后关系的Meta分析[J]. 中南医学科学杂志, 2021, 49(4):418-422. [18] SUDA K, MITSUDOMI T, SHINTANI Y, et al. Clinical impacts of EGFR mutation status:analysis of 5780 surgically resected lung cancer cases[J]. Ann Thorac Surg, 2021, 111(1):269-276. [19] 许丽莉, 郭人花. Ki67表达及EGFR突变对Ⅰ期肺腺癌患者术后复发转移风险的相关分析[J]. 中国肺癌杂志, 2022, 25(12):852-861. [20] ITO M, MIYATA Y, TSUTANI Y, et al. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype:a retrospective multi-center analysis[J]. Lung Cancer, 2020, 141:107-113. [21] 卢畅, 申淑景, 毛玉焕, 等. CEA、CYFRA21-1、NSE水平与EGFR突变的晚期肺腺癌患者临床疗效的相关性[J]. 肿瘤防治研究, 2017, 44(7):485-488. |